Monoclonal antibodies to fibroblast growth factor receptor 2
AssigneeGalaxy Biotech, LLC
InventorsKyung Jin Kim, Wei-meng Zhao, Hangil Park, Maximiliano Vasquez
Life of this patent
Estimating the term…
Abstract
The present invention is directed toward a monoclonal antibody to fibroblast growth factor receptor 2, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient.
Claims15
1-20. (canceled)
A mammalian cell line producing a monoclonal antibody (mAb) that binds human fibroblast growth factor receptor 2 isoform IIIb (FGFR2 IIIb) comprising a light chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 24-34, 50-56, and 89-97 of SEQ ID NO. 1 and comprising a heavy chain variable region comprising CDR1, CDR2, and CDR3 respectively defined by residues 31-35, 50-66 and 99-103 of SEQ ID NO:4.
Dependencies are inferred from the claim text.